Erlotinib (Tarceva) vs. Standard Chemotherapy (Paclitaxel and Carboplatin) in Patients With Advanced NSCLC and ECOG PS 2

This study is ongoing, but not recruiting participants.

Study NCT00085839 Information provided by OSI Pharmaceuticals

First Received: June 15, 2004 Last Updated: November 3, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)